Clinical trials: Diminished Pleasure
Cocaine-Related Disorders, Anhedonia
Targeting Anhedonia in Cocaine Use Disorder
The purpose of this study is to examine anhedonia as a potential moderator of treatment outcomes for Cocaine Use Disorder (CUD).
- Trial name
- NCT02773212
- Testing
- d-amphetamine, Contingency management
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Illinois Chicago
Anhedonia
Development of a Novel Transdiagnostic Intervention for Anhedonia - R61 Phase
The overall goal of this project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA), using ultra-high field functional neuroimaging.
- Trial name
- NCT02874534
- Testing
- Behavioral Activation, Mindfulness Treatment
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of North Carolina, Chapel Hill
Anhedonia
Development of a Novel Transdiagnostic Intervention for Anhedonia - R33 Phase
The overall goal of this project is to develop a novel transdiagnostic treatment for anhedonia, called Behavioral Activation Treatment for Anhedonia (BATA), using ultra-high field functional neuroimaging.
- Trial name
- NCT04036136
- Testing
- Behavioral Activation, Mindfulness Treatment
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- University of North Carolina, Chapel Hill
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences